z-logo
Premium
Inhibition of rat cervical epithelial cell growth by heparin and its reversal by EGF
Author(s) -
Wright Thomas C.,
Johnstone Theresa V.,
Castellot John J.,
Karnovsky Morris J.
Publication year - 1985
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.1041250320
Subject(s) - dermatan sulfate , heparin , glycosaminoglycan , epidermal growth factor , extracellular matrix , chondroitin sulfate , hyaluronic acid , cell growth , growth factor , chondroitin , microbiology and biotechnology , biology , heparan sulfate , chemistry , biochemistry , anatomy , receptor
Abstract The effects of heparin on the in vitro growth of rat cervical epithelial cells were examined. Heparin was found to inhbit in a dose dependent fashion the log‐phase growth of rat cervical epithelial cells (RCEC) grown in the absence of medium supplements. An inhibition of growth is observed at concentrations as low as 500 ng/ml and 50% inhibition of growth occurs at a concentration of 5 μ/ml. The growth inhibitory activity of heparin is independent of anticoagulant activity since three separate non‐anticoagulant preparations of heparin all inhibit growth. Other glycosaminoglycans including chondroitin 4‐sulfate, chondroitin 6‐sulfate, dermatan sulfate, hyaluronic acid, and keratin sulfate do not inhibit the growth of rat cervical epithelial cells. The ability of heparin to inhibit the log‐phase growth of rat cervical epithelial cells is dependent on the composition of the medium in which the cells are grown. The addition of ≥ 7.5 ng/ml epidermal growth factor to epithelial cultures blocks the growth inhibitory activity of heparin. These results suggest that components of the extracellular matrix modulate the growth responses of epithelial cells and may be important in regulating cellular proliferation in normal and pathological states.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here